Skip to main content

Ciphergen Stock Downgraded By Second Bank in Two Months

NEW YORK, Aug. 4 (GenomeWeb News) - Merriman Curhan Ford today downgraded Ciphergen shares to 'sell' from 'neutral,' the the brokerage and investment bank said.


The downgrade comes as Ciphergen shares continue to slide after the company reported lackluster sales during the second quarter.


The downgrade is the second in as many months to hit Ciphergen: Piper Jaffray on July 1 downgraded the stock to 'underperform' from 'outperform.'


Shares in the Fremont, Calif.-based protein chip company were trading down 15.5 percent, or $.49, at $2.87 on the Nasdaq exchange late this morning. The shares closed at $4.10 on July 30. Ciphergen issued its second-quarter earnings after the market closed that day.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.